Rockefeller Capital Management’s AnaptysBio ANAB Stock Holding History

Rockefeller Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3K	Sell	153 -173	-53%	-$10.5K	﹤0.01%	4005
2026 Q1	$18.1K	Buy	326 +261	+402%	+$14K	﹤0.01%	3747
2025 Q4	$3.15K	Buy	+65	New	+$2.53K	﹤0.01%	4203
2019 Q4	–	Sell	-1,951	Closed	-$68K	–	2038
2019 Q3	$68K	Sell	1,951 -81	-4%	-$3.85K	﹤0.01%	893
2019 Q2	$115K	Hold	2,032	–	–	﹤0.01%	662
2019 Q1	$148K	Hold	2,032	–	–	﹤0.01%	663
2018 Q4	$130K	Hold	2,032	–	–	﹤0.01%	434
2018 Q3	$203K	Buy	+2,032	New	+$169K	﹤0.01%	346

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Rockefeller Capital Management's ANAB Position: Q2 2026 in Review

Rockefeller Capital Management reduced its AnaptysBio (ANAB) stake by 53% in Q2 2026, selling an estimated $10.5K and leaving 153 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4005.

Rockefeller Capital Management first reported a position in ANAB in Q3 2018 and has held it in 8 quarters since. The position peaked at $203K in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Rockefeller Capital Management held 153 shares of AnaptysBio worth $10.3K as of Q2 2026.
Rockefeller Capital Management sold 173 AnaptysBio shares in Q2 2026, an estimated $10.5K.
AnaptysBio made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4005 holding.
Rockefeller Capital Management first reported a position in AnaptysBio in Q3 2018 and has held it in 8 quarters since.
Rockefeller Capital Management's AnaptysBio position peaked at $203K in Q3 2018.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.